LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Home・Stock List・Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc

Open

Sector Healthcare

0.92 4.55

Buy Sell

Overview

Share price change

24h

Current

Min

0.89

Max

0.94

Key metrics
By Trading Economics
Sales	34M
EPS	-0.36
Employees	325

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+381.11 upside

Dividends
By Dow Jones
Next Earnings	5 Nov 2024

Market Stats
By TradingEconomics
Market Cap	1.2M 154M
Previous open	-3.63
Previous close	0.92

News Sentiment

By Acuity

50%

167 / 390 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

0.8999 / 0.9898 Support & Resistance

Karyopharm Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

3 Nov 2024, 23:05 UTC

Top News

Fitch Affirms Australia's Sovereign AAA Rating, But Warns Of Mounting Budget Risks

3 Nov 2024, 21:12 UTC

Earnings

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects -- Update

3 Nov 2024, 20:59 UTC

Earnings

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects

3 Nov 2024, 23:34 UTC

Top News

Stocks Poised for Lower Open -- Barrons.com

3 Nov 2024, 23:16 UTC

Top News

Earnings

Berkshire Hathway Earnings Weren't as Bad as They Looked -- Barrons.com

3 Nov 2024, 22:50 UTC

Acquisitions, Mergers, Takeovers

Santos Says Working Interest in PNG LNG Now 39.9%

3 Nov 2024, 22:50 UTC

Acquisitions, Mergers, Takeovers

Santos Says Kumul to Assume $90 Million of Project Finance Debt Associated With Stake

3 Nov 2024, 22:49 UTC

Acquisitions, Mergers, Takeovers

Santos Says Final Payment Takes Total Cash Consideration to $602 Million

3 Nov 2024, 22:49 UTC

Acquisitions, Mergers, Takeovers

Santos Receives Final $241 Million Payment From Kumul

3 Nov 2024, 22:48 UTC

Acquisitions, Mergers, Takeovers

Santos Completes Sale of 2.6% Interest in PNG LNG to Kumul Petroleum

3 Nov 2024, 20:37 UTC

Earnings

Westpac FY 2024 Deposits Increased 5% to A$674 Billion

3 Nov 2024, 20:37 UTC

Earnings

Westpac FY 2024 Loans Increased 4% to A$807 Billion

3 Nov 2024, 20:37 UTC

Earnings

Westpac FY 2024 Impairment Charges 7 Bps of Loans

3 Nov 2024, 20:37 UTC

Earnings

Westpac FY 2024 Operating Expenses A$10.94 Billion, Up 7% Excluding Notable Items

3 Nov 2024, 20:36 UTC

Earnings

Westpac FY 2024 Non-Interest Income A$2.84 Billion, Down 15%

3 Nov 2024, 20:35 UTC

Earnings

Westpac FY 2024 CET1 Level 2 Capital Ratio 12.5%, Up 11 Bps

3 Nov 2024, 20:35 UTC

Earnings

Westpac Raises Share Buyback Program by A$1 Billion

3 Nov 2024, 20:35 UTC

Earnings

Westpac Final Dividend A$0.76/Share

3 Nov 2024, 20:33 UTC

Earnings

Westpac FY 2024 Net Interest Margin Down 1 Bps at 1.95%

3 Nov 2024, 20:32 UTC

Earnings

Westpac FY 2024 Revenue A$21.59 Billion, Flat on FY 2023

3 Nov 2024, 20:32 UTC

Earnings

Westpac FY Net Profit A$6.99 Billion, Down 3%

3 Nov 2024, 18:09 UTC

Top News

Boeing Had a Big Week. This One Is Even Bigger. -- Barrons.com

3 Nov 2024, 10:30 UTC

Top News

Fed Prepares Rate Cut Amid Economic Contradictions -- WSJ

3 Nov 2024, 03:00 UTC

Top News

Disgraced Lebanese Central Banker Who Was a Fugitive Now Awaits His Fate -- WSJ

2 Nov 2024, 13:53 UTC

Top News

Earnings

Acquisitions, Mergers, Takeovers

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2 Nov 2024, 13:44 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 Nov 2024, 13:00 UTC

Top News

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2 Nov 2024, 12:58 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 Nov 2024, 12:48 UTC

Top News

Earnings

Acquisitions, Mergers, Takeovers

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2 Nov 2024, 12:32 UTC

Earnings

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

381.11% upside

12 Months Forecast

Average 4.33 USD 381.11%

High 7 USD

Low 2 USD

Based on 6 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Karyopharm Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.8999 / 0.9898Support & Resistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

167 / 390 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe, in combination with dexamethasone to treat adult patients with multiple myeloma. It is also developing treatments for other diseases.